Effects of breast cancer resistance protein inhibitors and pharmaceutical excipients on decreasing gastrointestinal toxicity of camptothecin analogs

Acta Pharmacologica Sinica

Volumn 29, Issue 11, 2008, Pages 1391-1398

  Zhang, Xin Xin ^a,b   Pan, Wei San ^b   Gan, Li ^a   Zhu, Chun Liu ^a   Gan, Yong ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Biliary excretion; Breast cancer resistance protein; CPT 11; Diarrhea; Gastrointestinal toxicity; Hydroxycamptothecin; Irinotecan

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CAMPTOTHECIN DERIVATIVE; CYCLOSPORIN A; ELACRIDAR; HYDROXYCAMPTOTHECIN; IRINOTECAN; MACROGOL 2000; POLOXAMER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BILIARY EXCRETION; CONTROLLED STUDY; DIARRHEA; DRUG BILE LEVEL; DRUG EFFECT; DRUG EXCRETION; GASTROINTESTINAL TOXICITY; INTESTINE INJURY; INTESTINE MUCOSA; MALE; NONHUMAN; RAT; WEIGHT CHANGE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOTRANSFORMATION; BREAST NEOPLASMS; CAMPTOTHECIN; DIARRHEA; EXCIPIENTS; GASTROINTESTINAL DISEASES; INTESTINAL MUCOSA; MALE; NEOPLASM PROTEINS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 55149084411     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2008.00883.x     Document Type: Article

References (30)

1. Jaxel C, Kohn KW, Wani MC, Wall ME, Pommier Y. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: Evidence for a specific receptor site and for a relation toantitumour activity. Cancer Res 1989 49 : 1465 69.
2. Atsumi R, Suzuki W, Hakusui H. Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion. Xenobiotica 1991 21 : 1159 69.
3. Yao Y, Sun YJ, Zhao H, Guo YW, Lin F, Cai X, et al. Short-term effects of chemotherapy combined with hydroxycamptothecine and oxaliplatin in treatment of recurrent and metastatic colorectal cancer. Chin J Cancer 2006 8 : 1035 8.
4. Kudoh S, Fukuoka M, Masuda N, Yoshikawa A, Kusunoki Y, Mastui K, et al. Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy of cisplatin. Jpn J Cancer Res 1995 86 : 406 13.
5. Negoro S, Fukuoka M, Masuda N, Takada M, Kusunoki Y, Mastui K, et al. Phase I study of weekly intravenous infusion of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 1991 83 : 1164 8.
6. Takasuna K, Kasai Y, Kitano Y, Mori K, Kakihata K, Hirohashi M, et al. Study on the mechanisms of diarrhea induced by a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats. Folia Pharmacol Jpn 1995 105 : 447 60.
7. Creemers GJ, Lund B, Verweij J. Topoisomerase I inhibitors: topo-tecan and irinotecan. Cancer Treat Rev 1994 20 : 73 96.
8. Kaneda N, Yokokura T. Nonlinear pharmacokinetics of CPT-11 in rats. Cancer Res 1990 50 : 1721 5.
9. Lokieo F, Canal P, Gay C, Chatelut E, Armand JP, Roche H, et al. Pharmacokinetics of irinotecan and its metabolites in human blood, bile, urine. Cancer Chemother Pharmacol 1995 36 : 79 82.
10. Gupta E, Lestingi TM, Mick R, Ramirez J, Yokes EE, Ratain MJ. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 1994 54 : 3723 5.
11. Takasuna K, Hagiwara T, Hirohashi M, Nomura M, Nagai E, Yokoiu T, et al. Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 1996 56 : 3752 7.
12. Zhang L, Li S, Liao H, Jiang WQ, Guan ZZ. Phase I trial of pharmacokinetics and human tolerability to 10-hydroxycamptothecin in patients with advanced malignancy. Chin J Cancer 2001 12 : 1391 5.
13. Huang HQ, Jiang WQ, Hu XH, Lin XB, Liu KF, Li YH, et al. Preliminary study of lyophilized 10-hydroxycamptothecin in advanced or recurrent malignancies. Chin J Cancer 2003 12 : 1334 8.
14. Horikawa M, Kato Y, Sugiyama Y Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats. Pharm Res 2002 19 : 1345 53.
15. Herwaarden AE, Schinkel AH. The function of breast cancer resistance protein in epithelial barriers, stem cells and milk secretion of drugs and xenotoxins. Trends Pharmcol Sci 2006 27 : 10 8.
16. Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003 22 : 7340 58.
17. Litman T, Brangi M, Hudson E, Fetsch P, Abati A, Ross DD, et al. The multidrug-resistant phenotype associated with overexpression of the new ABC halftransporter, MXR (ABCG2). J Cell Sci 2000 113 : 2011 21.
18. Kruijtzer CMF, Beijnen JH, Rosing H, Bokkel Huinink WW, Schot M, Jewell RC, et al. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and p-glyco-protein inhibitor GF120918. J Clin Oncol 2002 20 : 2943 50.
19. Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH, et al. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 2000 92 : 1651 6.
20. Jonker JW, Buitelaar M, Wagenaar E, Van Der Valk MA, Scheffer GL, Scheper RJ, et al. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci USA 2002 99 : 15649 54.
21. Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acrido-necarboxamide derivative. Cancer Res 1993 53 : 4595 602.
22. Gupta A, Dai Y, Vethanayagam RR, Hebert MF, Thummel KE, Unadkat JD, et al. Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. Cancer Chemother Pharmacol 2006 58 : 374 83.
23. Yamagata T, Kusuhara H, Morishita M, Takayama K, Benameur H, Sugiyama Y Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients. Drug Metab Dispos 2007 35 : 1142 8.
24. Takasuma K, Hagiwara T, Watanabe K, Onose S, Yoshida S, Kumazawa E, et al. Optimal antidiarrhea treatmeat for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea. Cancer Chemother Pharmacol 2006 58 : 494 503.
25. Hendricks CB, Rowinsky EK, Grochow LB. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res 1992 52 : 2268 78.
26. Brangi M, Litman T, Ciotti M, Nishiyama K, Kohlhagen G, Takimoto C, et al. Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res 1999 59 : 5938 46.
27. Yamagata T, Kusuhara H, Morishita M, Takayama K, Benameur H, Sugiyama Y Effect of excipients on breast cancer resistance protein substrate uptake activity. J Controlled Release 2007 124 : 1 5.
28. Batrakova EV, Li S, Elmquist WF, Miller DW, Alakhov VY, Kabanov AV. Mechanism of sensitization of MDR cancer cells by pluronic block copolymers: selective energy depletion. Br J Cancer 2001 85 : 1987 97.
29. Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 1993 11 : 909 13.
30. Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated nonsmall-cell lung cancer. J Clin Oncol 1992 10 : 16 20.